A 2026 clinical study examined how NMN and NR (1,200 mg/day) affect NAD+ levels in both blood and brain.

Key Points:

• Blood NAD+ increased gradually and plateaued after ~2 weeks
• Brain NAD+ rose to about 40% above baseline after 4 weeks
• Effects were consistent in both healthy individuals and Parkinson’s patients
• NAD+ declined gradually over 2–3 weeks after stopping

This is one of the clearer human timelines for NAD+ kinetics. The data suggests NAD+ elevation is cumulative, not immediate, and requires consistent intake over weeks to fully manifest, especially in the brain.

Full Article: https://renuebyscience.com/blogs/scientific-evidence-library/nmn-nr-increase-nad-in-blood-and-brain

Would you consider a molecule like NMN for fertility support if the evidence looked promising in mice, or is that still too far from human reality?

TL;DR
A new mouse study found that NMN improved ovarian function, egg quality, and embryo development in aged mice, but the benefits were strongly dose-dependent and not proven in humans.

Quick Takeaways

• This paper tested whether NMN can improve ovarian aging and egg quality in older female mice.
• The researchers used both live-animal dosing and embryo culture experiments, then measured follicles, mitochondrial function, oxidative stress, and embryo development.
• The headline result is interesting, but it is still a mouse study with short treatment windows and no human fertility outcomes.

Context

Female reproductive aging is one of the clearest examples of biology running into an energy problem. As ovaries age, egg quality drops, mitochondrial function worsens, reactive oxygen species rise, and the pool of healthy follicles shrinks. That matters not only for fertility, but also for embryo viability and the success of assisted reproduction.

NMN, short for nicotinamide mononucleotide, sits upstream of NAD+, a molecule central to cellular energy metabolism. NAD+ tends to decline with age in many tissues, and that has made NMN a popular candidate in aging research. The basic idea is simple: if aging eggs are partly failing because they are energy-starved and oxidatively stressed, maybe restoring NAD+ could help rescue mitochondrial performance.

That is the question this paper tackled. The authors studied naturally aged female mice, gave them different NMN doses for 10 days, and looked at ovarian reserve, egg quality, and embryo development. They also tested NMN directly in embryo culture media after fertilization. The results are more nuanced than “NMN reverses aging,” but they are genuinely interesting.

What the researchers actually did

The study had two main parts. First, the authors ran an in vivo mouse experiment using young females aged 8 to 12 weeks and older females aged 11 to 12 months. In the dose-finding phase, aged mice received NMN at 200, 500, or 1000 mg/kg/day for 10 days, while young and aged controls got saline. Each group had 8 mice. Based on follicle counts and ovulated oocyte numbers, the authors selected 500 mg/kg/day as the “best” dose for the deeper mechanistic experiments.

They then used larger groups of 33 mice each for young controls, aged controls, and aged mice treated with 500 mg/kg/day NMN. After the same 10-day treatment, they measured ovarian NAD+ and ATP, along with oocyte reactive oxygen species, apoptosis, calcium levels, and mitochondrial membrane potential. They also looked at the expression of SIRT1, PGC-1α, and TOMM20, which are all tied to mitochondrial maintenance and biogenesis.

The second part was an in vitro fertilization and embryo culture experiment. Zygotes from aged mice were cultured with 0, 1, 10, or 100 µM NMN, while embryos from young mice were cultured without NMN as a reference. The main endpoints were fertilization rate, 4/8-cell development, morula formation, and blastocyst formation. That setup let the authors ask two related but different questions: does NMN help the aging ovary in the animal, and can NMN directly improve embryo development in culture?

The main finding: moderate NMN helped, more was not better

This is the part most people will care about. In aged mice, ovarian reserve was lower than in young mice, which is exactly what you would expect. But 500 mg/kg/day NMN increased total follicle number and increased the number of ovulated oocytes after superovulation. By contrast, 200 mg/kg/day did not produce a clear benefit, and 1000 mg/kg/day actually looked worse in some follicle measures, including a significant drop in primary follicles. That is a classic non-linear dose response: too little did not do much, the middle dose helped, and the highest dose may have been counterproductive.

The embryo culture data showed the same pattern. Compared with aged controls, 1 µM NMN improved fertilization and downstream development the most. Fertilization rose from 25.17% in aged controls to 72.94% with 1 µM NMN, while blastocyst formation rose from 21.56% to 68.98%. At 10 µM, the embryos still did better than untreated aged controls, but not as well as 1 µM. At 100 µM, the benefit largely disappeared.

That point matters because supplement discourse often assumes higher doses should work better. This study suggests the opposite may be true in reproductive biology. The authors themselves discuss possible reasons, including transporter saturation, impaired NMN utilization in aged oocytes, and metabolic stress from excessive NAD+-related pathway activation. Those are still hypotheses here, but they fit the data better than a simple “more NMN equals more benefit” model.

Why mitochondria are the center of the story

Mechanistically, the paper is built around mitochondria. The authors found that aged ovaries had lower NAD+ and ATP levels, while NMN raised both. Aged oocytes also showed more ROS, more apoptosis, higher intracellular calcium, and lower mitochondrial membrane potential. NMN shifted all of those in the healthier direction. In plain language, the eggs looked less oxidatively stressed and their mitochondria looked more functional after treatment.

The signaling story is also plausible. NMN increased expression of SIRT1, PGC-1α, and TOMM20 in aged mouse ovarian tissue and oocytes. SIRT1 is an NAD+-dependent deacetylase often linked to stress resistance and mitochondrial regulation. PGC-1α is one of the best-known controllers of mitochondrial biogenesis. TOMM20 is part of the machinery that imports proteins into mitochondria. Together, those markers support the authors’ model that NMN is not just changing one redox measurement, but may be improving mitochondrial quality control more broadly.

That said, this is still a mechanistic association, not a definitive proof chain. The study did not use knockout animals to show that blocking SIRT1 or PGC-1α eliminates the NMN effect. So the pathway is well-motivated, but not fully nailed down.

How convincing is this, really?

As mouse reproductive-aging papers go, this one is fairly solid. It used naturally aged mice rather than an extreme toxin model, looked at multiple endpoints, and showed internal consistency across ovarian reserve, egg stress markers, and embryo development. The dose-response findings also make the study more believable, not less. Biology often behaves like that.

But there are important caveats. First, this was a short intervention: only 10 days of NMN treatment in vivo. That is enough to test a signal, but not enough to answer long-term safety, durability, or whether repeated cycles would still help. Second, mice are not humans, and mouse ovarian aging does not map perfectly onto human fertility decline. Third, the paper measured embryo development up to blastocyst, not live birth or offspring health. Better blastocysts are encouraging, but they are not the same thing as healthy babies.

There is also a practical translation problem. The doses used in mice, especially 500 mg/kg/day, are not something people should casually map onto human supplement habits. And because the paper found that excessive dosing might reduce benefit, self-experimentation becomes even harder to justify.

So my read is this: the study strengthens the case that NAD+ metabolism is involved in reproductive aging, and it suggests NMN is worth further investigation. But it does not justify saying NMN “restores fertility” in women. It shows a promising signal in aged mice, under tightly controlled conditions, with a surprisingly narrow effective window.

The broader implication is less about NMN as a miracle compound and more about reproductive aging as a mitochondrial problem that may be partly modifiable. That is a scientifically interesting idea, and this paper gives it more support. The real question now is whether any of this survives the jump from mouse ovaries to human reproductive medicine.

What do you think is more important here: the encouraging embryo data, or the warning that the dose-response curve may be much less forgiving than supplement culture assumes?

Informational only

Reference: https://link.springer.com/article/10.1007/s43032-026-02092-w

If regular movement helps preserve muscle function with age, could part of that pattern be associated with higher muscle NAD+ levels?

TL;DR

In a human muscle study, older adults had lower muscle NAD+ than younger adults, but exercise-trained older adults looked much closer to the young group than physically impaired peers.

Quick Takeaways

• This study looked at how skeletal muscle metabolism changes with aging, with a special focus on NAD+, a central molecule in cellular energy metabolism.
• Researchers analyzed muscle biopsies from young adults and three groups of older adults: trained, normally active, and physically impaired.
• The main finding was associative rather than causal: lower muscle NAD+ tracked with poorer muscle and mitochondrial health, while exercise-trained older adults had NAD+ levels much closer to those of younger adults.

Context

Aging muscle does not just get smaller or weaker. It also changes metabolically. Mitochondria tend to function less efficiently, insulin sensitivity often declines, and older muscle becomes less adaptable under stress. That matters because skeletal muscle is one of the major tissues supporting mobility, glucose handling, metabolic health, and resilience later in life.

One molecule that repeatedly appears in aging research is NAD+ (nicotinamide adenine dinucleotide). NAD+ helps shuttle electrons for energy production and also serves enzymes involved in DNA repair, stress responses, and mitochondrial regulation. In animal studies, NAD+ often declines with age, and raising it can improve some aspects of physiology. Human evidence has been less consistent. This paper tried to narrow that gap by asking a simple but important question: does NAD+ actually fall in aging human muscle, and if so, is that linked to muscle health in real people? The study suggests yes, with a major caveat: this was a cross-sectional design, so it supports association more than causation.

What the researchers actually did

The study included 52 people total: 12 young adults aged 20–30, plus 40 older adults aged 65–80. The older participants were divided into three groups: 17 exercise-trained older adults, 17 older adults with normal activity levels, and 6 physically impaired older adults. The trained group had performed at least three structured exercise sessions per week for at least one year. The impaired group was defined by a Short Physical Performance Battery score of 9 or below.

This design is more informative than a simple young-versus-old comparison because it allows the researchers to ask whether metabolic differences track not only with age, but also with healthier versus less healthy aging muscle states. That matters, because two older adults of the same age can have very different muscle biology depending on training, function, and physical capacity.

Participants wore activity monitors for 5 days. Young adults and the “normal” older adults both averaged about 10,000 steps per day, which helps reduce the chance that every age effect is merely a fitness effect. The trained older adults averaged roughly 13,000 steps per day and spent more time in high-intensity activity, whereas the impaired group averaged closer to 6,000 steps per day. Researchers then took vastus lateralis muscle biopsies and used mass spectrometry-based metabolomics to profile 137 annotated metabolites. They also assessed mitochondrial respiration, mitochondrial protein abundance, muscle strength, muscle volume, exercise efficiency, and in vivo mitochondrial function.

That combination is one of the strengths of the paper. It was not just a single-metabolite observation; it connected metabolite abundance to actual physiological and functional parameters.

NAD+ stood out

Among the 137 muscle metabolites measured, NAD+ was one of the most clearly depleted in older adults compared with young adults. More importantly, it followed a graded pattern across the groups. The physically impaired older adults had the lowest NAD+ levels. The normally active older adults were also lower than the young group. But the exercise-trained older adults had NAD+ levels much closer to those of young adults. This pattern is visible in Figure 2 on page 3, where NAD+ also shows the strongest association with the study’s “healthy aging” trend.

So the finding was not simply that older age was associated with less NAD+, but that healthier muscle aging profiles were associated with more preserved NAD+.

The paper also found the opposite pattern for oxidative stress-related signals. Ophthalmic acid, a marker associated with oxidative stress, was higher in older adults and highest in the impaired group, while being less elevated in the trained group. Oxiglutathione showed a similar trend. In plain language, lower NAD+ tended to appear in the same biological setting as more oxidative stress and poorer muscle status. That does not prove oxidative stress is causing NAD+ loss, or vice versa, but it does support the idea that they are part of the same aging muscle phenotype.

Why this matters for muscle function

The more useful question is whether this biochemical pattern relates to how muscle actually performs. Here, the answer was yes, at least associationally.

Across the older adults, higher muscle NAD+ was positively associated with mitochondrial respiration. In Figure 4 on page 5, the reported correlation between NAD+ abundance and maximal ADP-stimulated mitochondrial respiration was R = 0.57, P = 0.00014. NAD+ was also positively associated with average daily step count, with R = 0.45, P = 0.0043. In other words, older adults whose muscles contained more NAD+ also tended to have better mitochondrial function and move more in daily life.

The study also identified potentially less favorable signals in the kynurenine pathway. Kynurenic acid was negatively associated with muscle strength, and kynurenine was negatively associated with exercise efficiency in the older adults. That broadens the picture: aging muscle is not just “low NAD+,” but a network shift involving energy metabolism, redox balance, and amino-acid-derived signaling molecules. Still, NAD+ emerged as one of the clearest metabolic markers associated with healthier muscle aging in this dataset.

What this does, and does not, say about boosting NAD+

This is where it is easy to overread the paper. The study supports the idea that muscle NAD+ is relevant to human muscle aging. It does not prove that taking an NAD+ precursor will recreate the physiology seen in the trained older adults.

The authors are careful on this point. They note that changing the NAD+ metabolome in humans does not automatically translate into the full physiological pattern seen with long-term exercise training, which suggests that NAD+ is likely one part of a broader muscle-health picture rather than the whole story. That means NAD+ may be important, but it may not be a single magic lever. Exercise changes blood flow, fiber recruitment, mitochondrial turnover, insulin signaling, inflammation, and many other pathways at once. Preserved NAD+ may be one component of that broader package rather than the whole story.

There are also real limitations. The study was cross-sectional, so reverse causation remains possible: people with healthier muscle biology may maintain higher NAD+, which then helps them stay active, rather than activity itself preserving NAD+. The impaired group was especially small, with only 6 participants, which limits confidence in finer subgroup differences. And muscle biopsies are heterogeneous, meaning the findings could reflect shifts in muscle fiber type or subcellular NAD+ pools rather than a uniform fall in NAD+ everywhere. The authors explicitly raise these issues in the discussion.

So the headline should stay measured: aging human muscle shows lower NAD+, and lower muscle NAD+ is associated with poorer muscle and mitochondrial health. That is a meaningful result, but not yet proof of a supplementation strategy.

Conclusion / Discussion Prompt

What I like about this paper is that it brings NAD+ down from the level of supplement discourse and back into actual human physiology. The most interesting signal here is not that NAD+ is “anti-aging.” It is that exercise-trained older adults seemed to preserve a more youthful-looking muscle metabolic profile, and NAD+ was one of the clearest markers associated with that pattern.

Informational only.

Reference: https://www.nature.com/articles/s43587-022-00174-3